Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Gomersall T, Spencer S, Basarir H, Tsuchiya A, Clegg J, Sutton A, Dickinson K. Measuring quality of life in children with speech and language difficulties: a systematic review of existing approaches. Int J Lang Commun Disord. 2015 Jul;50(4):416-35. doi: 10.1111/1460-6984.12147